Company Description
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests.
The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions.
It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA.
The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
| Country | United States |
| Founded | 1991 |
| IPO Date | Oct 5, 1995 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,700 |
| CEO | Samraat Raha |
Contact Details
Address: 322 North 2200 West Salt Lake City, Utah 84116 United States | |
| Phone | 801 584 3600 |
| Website | myriad.com |
Stock Details
| Ticker Symbol | MYGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000899923 |
| CUSIP Number | 62855J104 |
| ISIN Number | US62855J1043 |
| Employer ID | 87-0494517 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Samraat S. Raha | President, Chief Executive Officer and Director |
| Mark S. Verratti | Chief Operating Officer |
| Dr. Dale Muzzey Ph.D. | Chief Scientific Officer |
| Paul J. Diaz J.D. | Consultant and Director |
| Benjamin R. Wheeler | Chief Financial Officer and Principal Accounting Officer |
| Matthew Scalo | Senior Vice President of Investor Relations |
| Jennifer L. Fox J.D. | Chief Legal Officer |
| Shereen Solaiman | Chief People Officer |
| Dr. Patrick M. Burke Ph.D. | Executive Vice President of Innovation and Strategic Partnerships |
| Dr. Thomas P. Slavin M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 4, 2026 | EFFECT | Notice of Effectiveness |
| Mar 4, 2026 | 424B3 | Prospectus |
| Feb 24, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 24, 2026 | 10-K | Annual Report |
| Feb 23, 2026 | 8-K | Current Report |
| Feb 11, 2026 | SCHEDULE 13G/A | Filing |
| Feb 9, 2026 | SCHEDULE 13G | Filing |
| Jan 13, 2026 | SCHEDULE 13G | Filing |
| Jan 12, 2026 | 8-K | Current Report |